MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MEN11467

CAS No. : 214487-46-4

MCE 站：MEN11467

产品活性：MEN11467 是一种有效的选择性拟肽速激肽 NK ₁ 受体拮抗剂。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：Neurokinin Receptor

In Vitro: MEN11467 potently inhibits the binding of [³H] substance P (SP) to tachykinin NK₁ receptors in the IM9 limphoblastoid cell line (pK_i=9.4±0.1). MEN11467 is highly specific for the human tachykinin NK₁ receptors, since it has negligible effects (pK_i<6) on the binding of specific ligands to tachykinin NK₂ or NK₃ receptors and to a panel of 30 receptors ion channels unrelated to tachykinin receptors. The antagonism exerted by MEN11467 at tachykinin NK₁ receptors is insurmountable in saturation binding experiments, both K_D and B_max of SP are significantly reduced by MEN11467 (0.3-10 nM). In the guinea-pig isolated ileum, MEN11467 (0.03-1 nM) produces a nonparallel rightward shift of the concentration-response curve to SP methylester with a concomitant reduction of the E_max to the agonist (pK_B=10.7±0.1). Moreover the antagonist activity of MEN11467 is hardly reversible despite prolonged washout. The pseudopeptide tachykinin NK₁ receptor antagonist, MEN11467 is used to study tachykininergic involvement in antigen-induced mucus secretion in ferret trachea in vitro. MEN11467 (1?nM-10?μM) inhibits [Sar⁹]SP-induced ³⁵SO₄, output in a concentration-dependent manner with an approximate IC₅₀ of 0.3 ?μM.

In Vivo: MEN11467 produces a long lasting (>2-3 h) dose-dependent antagonism of bronchoconstriction induced by the selective tachykinin NK₁ receptor agonist, [Sar⁹, Met(O₂)¹¹]SP in anaesthetized guinea-pigs (ID₅₀s=29±5, 31±12 and 670±270 μg/kg, after intravenous, intranasal and intraduodenal administration, respectively), without affecting bronchoconstriction induced by methacholine. After oral administration MEN11467 produces a dose-dependent inhibition of plasma protein extravasation induced in guinea-pig bronchi by [Sar⁹, Met(O₂)¹¹] (ID₅₀= 6.7±2 mg/kg) or by antigen challenge in sensitized animals (ID₅₀=1.3 mg/kg). After i.v. administration MEN11467 weakly inhibits the GR 73632-induced foot tapping behaviour in gerbil (ED₅₀=2.96±2 mg/kg), indicating a poor ability to block central tachykinin NK₁ receptors. Treatment with MEN11467 (1 mmol/kg twice weekly for 2 weeks) results in a temporary growth arrest of the U373 MG xenograft that last for about 10 days until the last MEN11467 administration (TVI%=56). Thereafter, the tumor start to regrow. MEN11467 anti-tumor activity is partially reverted by the simultaneous administration of an equimolar dose of exogenous substance P (SP), suggesting the specificity of tachykinin NK1 receptor activation in glioma growth. Prolonged s.c. treatment with a higher MEN11467 dose (1.7 mmol/kg at five times a week for 6 weeks) completely inhibits the growth of U373 MG tumor for the entire length of the experiment, even following administration of a low exogenous SP dose. After 6 weeks, the tumor mass is not increased compared to the untreated control with TVI%=96%.

相关产品：Substance P  |  Aprepitant  |  Netupitant  |  Senktide  |  Fosaprepitant dimeglumine  |  SB-222200  |  Maropitant  |  Vapreotide  |  Neurokinin A TFA  |  Neurokinin B TFA  |  Saredutant  |  Talnetant  |  Vofopitant  |  L-732138  |  NKP608  |  [Sar9,Met(O2)11]-Substance P TFA  |  Eprazi dihydrochloride  |  Y1 receptor antagonist 1  |  Substance P(1-7) TFA  |  GR 159897  |  Men 10376 TFA  |  Neurokinin A(4-10) TFA  |  Osanetant

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。